Endo International Target of Unusually High Options Trading (NASDAQ:ENDP)

Endo International plc (NASDAQ:ENDPGet Rating) (TSE:ENL) was the target of unusually large options trading on Wednesday. Traders purchased 14,075 call options on the company. This is an increase of approximately 572% compared to the typical daily volume of 2,095 call options.

Analyst Upgrades and Downgrades

ENDP has been the topic of a number of recent research reports. Piper Sandler downgraded Endo International from a “neutral” rating to an “underweight” rating and dropped their price target for the stock from $3.00 to $1.00 in a research report on Friday, May 6th. Barclays lowered their price target on Endo International from $2.00 to $1.00 in a research note on Monday, May 9th. StockNews.com began coverage on Endo International in a research report on Friday, July 29th. They set a “hold” rating on the stock. Finally, BMO Capital Markets reduced their target price on Endo International from $4.00 to $2.00 in a research report on Monday, May 9th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $3.00.

Institutional Investors Weigh In On Endo International

Hedge funds have recently made changes to their positions in the business. NorthCrest Asset Manangement LLC bought a new stake in shares of Endo International during the first quarter valued at approximately $28,000. First Quadrant LLC CA bought a new stake in Endo International during the first quarter worth approximately $36,000. Nisa Investment Advisors LLC raised its holdings in Endo International by 500.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 18,000 shares of the company’s stock worth $57,000 after purchasing an additional 15,000 shares in the last quarter. Campbell & CO Investment Adviser LLC bought a new stake in Endo International during the fourth quarter worth approximately $68,000. Finally, Carolina Wealth Advisors LLC raised its holdings in Endo International by 20.2% during the first quarter. Carolina Wealth Advisors LLC now owns 29,862 shares of the company’s stock worth $69,000 after purchasing an additional 5,028 shares in the last quarter. Institutional investors own 80.39% of the company’s stock.

Endo International Price Performance

Shares of Endo International stock opened at $0.64 on Friday. The company has a market capitalization of $150.00 million, a PE ratio of -0.20 and a beta of 1.15. Endo International has a 1-year low of $0.28 and a 1-year high of $7.07. The business has a 50-day moving average of $0.47 and a 200-day moving average of $1.71.

Endo International (NASDAQ:ENDPGet Rating) (TSE:ENL) last issued its earnings results on Thursday, May 5th. The company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.22. The company had revenue of $652.26 million during the quarter, compared to the consensus estimate of $637.09 million. Endo International had a negative return on equity of 72.22% and a negative net margin of 24.82%. Endo International’s quarterly revenue was down 9.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.73 earnings per share. On average, equities analysts expect that Endo International will post 0.78 earnings per share for the current fiscal year.

About Endo International

(Get Rating)

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology.

Read More

Want More Great Investing Ideas?

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.